Immunoway/AG-221(Enasidenib)/10mg 50mg 100mg/MC0921
市场价：
¥6000.00
美元价：
3000.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
AG-221(Enasidenib)
- Catalog No.：MC0921
- Data Sheet
- MSDS
- Support
- Description
- References ( 0 )
- Protocol
- CasNo：
- 1446502-11-9
- MolecularFormula：
- C19H17F6N7O
- Purity：
- >98%
- Target：
- Isocitrate Dehydrogenase (IDH)
- IC50：
- No data
- In Vitro：
- Enasidenib (AG-221) reverses the effects of mutant IDH2 on DNA methylation in mutant stem/progenitor cells. Enasidenib induces differentiation and impairs self-renewal of IDH2-mutant leukemia cells, effects that are further enhanced by simultaneous inhibition of Flt3ITD. Enasidenib (AG-221) therapy induces differentiation of leukemic cells, with an increase in the CD11b+ population and a decrease in the c-Kit+ population in the peripheral blood at 2wks[2].
- In Vivo：
- Treatment with Enasidenib (AG-221) significantly improves survival in an IDH2-mutant acute myeloid leukemia (AML) primary xenograft mouse model[1]. Enasidenib (AG-221), a mutant IDH2 inhibitor, remodels the epigenetic state of IDH2-mutant cells and induces alterations in self-renewal/differentiation in IDH2-mutant AML model in vivo. Enasidenib treatment (10mg/kg or 100mg/kg bid) leads to a reduction in 2-HG in vivo (96.7% below pre-treatment levels). Moreover, Enasidenib treatment restores megakaryocyte-erythroid progenitor (MEP) differentiation that is suppressed by mutant IDH2 expression (mean MEP% mean, 39% Veh vs 50% AG-221). Enasidenib therapy reverses the effects of mutant IDH2; a significant reduction is observed in DNA methylation, including 180 genes that have 20 or more hypomethylated differentially methylated cytosines (DMCs) following treatment. Enasidenib (100mg/kg bid) treatment of mice engrafted with Mx1-Cre IDH2R140QFlt3ITD AML cells markedly reduces 2-hydroxyglutarate
- Fields：
- AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein.
- Specificity：
- Target: Isocitrate Dehydrogenase (IDH) . Fields: AG-221 is an orally available, selective, potent inhibitor of the mutated IDH2 protein.
- Source：
- Rabbit
- Dilution：
- WB 1:500-2000
- Concentration：
- >98%
- Storage Stability：
- 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO
- Other Name：
- AG221,AG 221
- MolecularWeight(Da)：
- 473.14
- References：
- [1]. Exploring the Pathway: IDH Mutations and Metabolic Dysregulation in Cancer Cells: A Novel Therapeutic Target. MAY 29, 2015 [2]. Alan H. Shih, et al. AG-221, a Small Molecule Mutant IDH2 Inhibit
- June 19-2018
- WESTERN IMMUNOBLOTTING PROTOCOL
- June 19-2018
- IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL
- June 19-2018
- IMMUNOFLUORESCENCE PROTOCOL
- September 08-2020
- FLOW-CYTOMEYRT-PROTOCOL
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN
- July 13-2018
- CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN
- July 13-2018
- CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN
- July 13-2018
- Antibody-FAQs
- Products Images
品牌介绍
ImmunowayImmunoWay Biotechnology，我们的使命是帮助世界各地的生命科学研究人员通过更好的产品和服务简化和加速他们的研究。我们专注于开发用于免疫学和细胞学检测的创新和可靠的产品。我们一直是开发高质量ELISA试剂盒，代谢检测试剂盒，抗体和抗体/蛋白质微阵列的先驱，参与癌症，细胞凋亡，细胞生长和信号转导。ImmunoWay Biotechnology，我们的使命是通过更好的产品和服务帮助世界各地的生命科学研究者简化和加速他们的研究。我们专注于开发创新和可靠的产品，用于免疫学和细胞学检测。我们一直是开发涉及癌症，细胞凋亡，细胞生长和信号转导的高质量ELISA试剂盒，代谢测定试剂盒，抗体和抗体/蛋白质微阵列的先驱。
品牌分类
\Elisa试剂盒\
联络我们
